Pacira BioSciences (PCRX) FY2025 results: revenue $726 million, up 3.6% on the year
Pacira BioSciences, Inc. (PCRX) reported revenue of $726 million for fiscal 2025, the year ended 31 December 2025, up 3.6% on the year before. Net income was $7 million, and diluted earnings per share $0.16. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2026.
Revenue
$726 million
+3.6% on the year
FY2018FY2025
Operating margin
2.6%
-10.5% a year earlier
FY2018FY2025
Net income
$7 million
FY2018FY2025
Diluted EPS
$0.16
FY2018FY2025
this yearthe year beforeHover a bar for its figure.
The year in brief
What management said about the year
Guidance figures: 9 new.
Full-year revenue rose four percent: Full-year total revenues rose 4 percent, and fourth-quarter revenues rose 5 percent to $196.9 million, the company reported.
Adjusted EBITDA declined year on year: Adjusted EBITDA was $38.7 million in the fourth quarter against $62.5 million a year earlier; full-year adjusted EBITDA was $186.5 million against $223.9 million.
EXPAREL volume drove fourth quarter: EXPAREL volume grew 7 percent in the fourth quarter, the company said, in a quarter it described as record-high EXPAREL sales.
SG&A rose on unplanned deal and legal costs: Fourth-quarter SG&A was $101.6 million, up from $79.6 million, which the company attributed to unanticipated business development diligence and litigation costs.
Buybacks reached 5.9 million shares in 2025: The company repurchased 2.0 million shares in the fourth quarter, and the full-year 2025 total reached 5.9 million shares.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2025
FY2024
FY2023
On the year
Last 8 years
Operating cash flow
152
189
155
-19.7%
Capital expenditure
15.3
10.6
15.2
+44.2%
Free cash flow
137
179
139
-23.5%
Free cash flow margin
18.8%
25.5%
20.7%
Cash from investing
99.5
-83.3
77.5
Cash from financing
-370
17.4
-183
Depreciation and amortisation
91.0
78.8
75.6
+15.5%
Share-based compensation
57.5
51.2
47.9
+12.4%
Buybacks
148
25.0
0.0
+493.3%
Diluted shares, weighted
45m
46m
52m
-2.6%
Shares outstanding at period end
41m
46m
46m
-11.1%
Balance sheet
$ million
FY2025
FY2024
FY2023
On the year
Last 8 years
Shareholders' equity
693
778
870
-11.0%
Debt
372
585
522
-36.4%
Operating lease liabilities
36.2
44.6
54.8
-19.0%
Other liabilities
163
145
127
+12.6%
Total liabilities and equity
1,265
1,554
1,574
-18.6%
Fixed assets
141
167
174
-15.8%
Goodwill
20.2
0.0
163
Intangible assets
368
426
483
-13.6%
Investments
79.9
208
128
-61.6%
Cash and equivalents
159
277
153
-42.7%
Receivables
124
113
106
+9.5%
Inventory
153
125
104
+22.0%
Other assets
221
237
263
-7.0%
Total assets
1,265
1,554
1,574
-18.6%
10-K for the year ended 31 December 2025, filed 26 February 2026: the filing.